These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 34506697

  • 1. Nitisinone treatment during two pregnancies and breastfeeding in a woman with tyrosinemia type 1 - a case report.
    Zöggeler T, Ramoser G, Höller A, Jörg-Streller M, Janzen N, Ramoni A, Scholl-Bürgi S, Karall D.
    J Pediatr Endocrinol Metab; 2022 Feb 23; 35(2):259-265. PubMed ID: 34506697
    [Abstract] [Full Text] [Related]

  • 2. First Scandinavian case of successful pregnancy during nitisinone treatment for type 1 tyrosinemia.
    Äärelä L, Nevalainen PI, Kurppa K, Hiltunen P.
    J Pediatr Endocrinol Metab; 2020 May 26; 33(5):661-664. PubMed ID: 32238608
    [Abstract] [Full Text] [Related]

  • 3. Long-term safety and outcomes in hereditary tyrosinaemia type 1 with nitisinone treatment: a 15-year non-interventional, multicentre study.
    Spiekerkoetter U, Couce ML, Das AM, de Laet C, Dionisi-Vici C, Lund AM, Schiff M, Spada M, Sparve E, Szamosi J, Vara R, Rudebeck M.
    Lancet Diabetes Endocrinol; 2021 Jul 26; 9(7):427-435. PubMed ID: 34023005
    [Abstract] [Full Text] [Related]

  • 4. Nitisinone: new drug. Type 1 tyrosinemia: an effective drug.
    Prescrire Int; 2007 Apr 26; 16(88):56-8. PubMed ID: 17458044
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Experience of nitisinone for the pharmacological treatment of hereditary tyrosinaemia type 1.
    Santra S, Baumann U.
    Expert Opin Pharmacother; 2008 May 26; 9(7):1229-36. PubMed ID: 18422479
    [Abstract] [Full Text] [Related]

  • 7. Effect of nitisinone (NTBC) treatment on the clinical course of hepatorenal tyrosinemia in Québec.
    Larochelle J, Alvarez F, Bussières JF, Chevalier I, Dallaire L, Dubois J, Faucher F, Fenyves D, Goodyer P, Grenier A, Holme E, Laframboise R, Lambert M, Lindstedt S, Maranda B, Melançon S, Merouani A, Mitchell J, Parizeault G, Pelletier L, Phan V, Rinaldo P, Scott CR, Scriver C, Mitchell GA.
    Mol Genet Metab; 2012 Sep 26; 107(1-2):49-54. PubMed ID: 22885033
    [Abstract] [Full Text] [Related]

  • 8. Clinical utilization of dried blood spot nitisinone (NTBC) and succinylacetone (SA) concentrations in hereditary tyrosinaemia type 1 - A UK centre experience.
    Yeo M, Turner C, Dalton NR, Rahman Y, Vara R.
    Ann Clin Biochem; 2020 Nov 26; 57(6):412-419. PubMed ID: 32936663
    [Abstract] [Full Text] [Related]

  • 9. Pregnancy in an NTBC-treated patient with hereditary tyrosinemia type I.
    Kassel R, Sprietsma L, Rudnick DA.
    J Pediatr Gastroenterol Nutr; 2015 Jan 26; 60(1):e5-7. PubMed ID: 23838819
    [No Abstract] [Full Text] [Related]

  • 10. Corneal depositions in tyrosinaemia type I during treatment with Nitisinone.
    Wisse RP, Wittebol-Post D, Visser G, van der Lelij A.
    BMJ Case Rep; 2012 Nov 30; 2012():. PubMed ID: 23203167
    [Abstract] [Full Text] [Related]

  • 11. Type 1 tyrosinemia in Finland: a nationwide study.
    Äärelä L, Hiltunen P, Soini T, Vuorela N, Huhtala H, Nevalainen PI, Heikinheimo M, Kivelä L, Kurppa K.
    Orphanet J Rare Dis; 2020 Oct 12; 15(1):281. PubMed ID: 33046095
    [Abstract] [Full Text] [Related]

  • 12. Simultaneous quantification of succinylacetone and nitisinone for therapeutic drug monitoring in the treatment of Tyrosinemia type 1.
    Sundberg J, Wibrand F, Lund AM, Christensen M.
    J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Jan 01; 1072():259-266. PubMed ID: 29195145
    [Abstract] [Full Text] [Related]

  • 13. Ophthalmic follow-up of patients with tyrosinaemia type I on NTBC.
    Gissen P, Preece MA, Willshaw HA, McKiernan PJ.
    J Inherit Metab Dis; 2003 Jan 01; 26(1):13-6. PubMed ID: 12872835
    [Abstract] [Full Text] [Related]

  • 14. Renal tubular function in children with tyrosinaemia type I treated with nitisinone.
    Santra S, Preece MA, Hulton SA, McKiernan PJ.
    J Inherit Metab Dis; 2008 Jun 01; 31(3):399-402. PubMed ID: 18509744
    [Abstract] [Full Text] [Related]

  • 15. [New drugs; nitisinone].
    Cohen AF, van Bronswijk H.
    Ned Tijdschr Geneeskd; 2006 Nov 18; 150(46):2541-2. PubMed ID: 17152330
    [Abstract] [Full Text] [Related]

  • 16. In brief: Nitisinone (Orfadin) for hereditary tyrosinemia.
    Med Lett Drugs Ther; 2016 Oct 10; 58(1505):e132. PubMed ID: 27701365
    [No Abstract] [Full Text] [Related]

  • 17. Early nitisinone treatment reduces the need for liver transplantation in children with tyrosinaemia type 1 and improves post-transplant renal function.
    Bartlett DC, Lloyd C, McKiernan PJ, Newsome PN.
    J Inherit Metab Dis; 2014 Sep 10; 37(5):745-52. PubMed ID: 24515874
    [Abstract] [Full Text] [Related]

  • 18. Monitoring tyrosinaemia type I: Blood spot test for nitisinone (NTBC).
    Sander J, Janzen N, Terhardt M, Sander S, Gökcay G, Demirkol M, Ozer I, Peter M, Das AM.
    Clin Chim Acta; 2011 Jan 14; 412(1-2):134-8. PubMed ID: 20883679
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of pre-symptomatic nitisinone treatment on long-term outcomes in Tyrosinemia type 1 patients: a systematic review.
    Geppert J, Stinton C, Freeman K, Fraser H, Clarke A, Johnson S, Sutcliffe P, Taylor-Phillips S.
    Orphanet J Rare Dis; 2017 Sep 11; 12(1):154. PubMed ID: 28893311
    [Abstract] [Full Text] [Related]

  • 20. The role of nitisinone in tyrosine pathway disorders.
    Lock E, Ranganath LR, Timmis O.
    Curr Rheumatol Rep; 2014 Nov 11; 16(11):457. PubMed ID: 25266991
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.